Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists.

Min,  Se Hee; Cho,  Young Min

doi:2015.16.4.252

J Korean Diabetes > Volume 16(4); 2015 > Article

Focused Issue

The Journal of Korean Diabetes 2015;16(4):252-259.
DOI: https://doi.org/10.4093/jkd.2015.16.4.252 Published online December 24, 2015.

글루카곤양 펩티드-1 수용체 작용제의 임상적 적용

민세희, 조영민

Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists.

Se Hee Min, Young Min Cho

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ymchomd@snu.ac.kr

Abstract

Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including deceleration of gastric emptying, decreased appetite, and increased satiety. Treatment with GLP-1 receptor agonists (GLP-1RAs) improves glycemic control in patients with type 2 diabetes without increasing the risk of hypoglycemia or weight gain. Current GLP-1RAs can be classified by their structure (exendin-4-based or human GLP-1-based), duration of action, and molecular size. Different GLP-1RAs exhibit different pharmacokinetics and pharmacodynamics. Herein we review the characteristics of available GLP-1RAs and discuss current issues such as insulin combination therapy and anti-obesity effects.

Key Words: Glucagon-like peptide 1, Obesity, Type 2 diabetes mellitus